Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection

Autor: Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J

Publikováno v: Journal of Clinical Medicine
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::140905e5bbb7c95b5e69e3ef0fb670dd
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6759

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.

Autor: Escudero-Sanchez R; Infectious Disease Department, University Hospital Ramon y Cajal, Madrid, Spain.; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0011), Instituto de Salud Carlos III, Madrid, Spain.; Instituto Ramón y Cajal Investigación Sanitaria (IRYCIS), Madrid, Spain., Muriel García A; Instituto Ramón y Cajal Investigación Sanitaria (IRYCIS), Madrid, Spain.; Biostatistics Unit, University Hospital Ramon y Cajal, Centro de Investigación Biomédica en Red, Epidemiología y Salúd Pública (CIBERESP), Universidad de Alcalá, Madrid, Spain., García Fernández S; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0011), Instituto de Salud Carlos III, Madrid, Spain.; Microbiology Department, University Hospital Ramon y Cajal, Madrid, Spain., Valencia Alijo A; Internal Medicine Department, University Hospital Puerta de Hierro, Majadahonda, Spain., Tasias Pitarch M; Infectious Disease Unit, University Hospital La Fe, Valencia, Spain., Merino De Lucas E; Internal Medicine Department, University Hospital General Alicante, Alicante, Spain., Gutierrez Rojas A; Internal Medicine Department, University Hospital Puerta de Hierro, Majadahonda, Spain., Ramos Martínez A; Internal Medicine Department, University Hospital Puerta de Hierro, Majadahonda, Spain., Salavert Lletí M; Infectious Disease Unit, University Hospital La Fe, Valencia, Spain., Giner L; Internal Medicine Department, University Hospital General Alicante, Alicante, Spain., Ruíz Ruigomez M; Internal Medicine Department, University Hospital 12 de Octubre, Madrid, Spain., García Basas L; Pharmacy Department, University Hospital Ramon y Cajal, Madrid, Spain., Fernández Fradejas J; Instituto Ramón y Cajal Investigación Sanitaria (IRYCIS), Madrid, Spain.; Pharmacy Department, University Hospital Ramon y Cajal, Madrid, Spain., Olmedo Sampedrio M; Internal Medicine Department, University Hospital Gregorio Marañón, Madrid, Spain., Cano Yuste A; Internal Medicine Department, University Hospital Reina Sofía, Córdoba, Spain., Díaz Pollán B; Internal Medicine Department, University Hospital La Paz, Madrid, Spain., Rodríguez Hernández MJ; Internal Medicine Department, University Hospital Virgen del Rocío, Sevilla, Spain., Martín Segarra O; Internal Medicine Department, University Hospital Fundación Alcorcón, Alcorcón, Spain., Sáez Bejar C; Internal Medicine Department, University Hospital La Princesa, Madrid, Spain., Armiñanzas Castillo C; Infectious Disease Department, University Hospital Marqués de Valdecilla, Santander, Spain., Gutiérrez B; Internal Medicine Department, University Hospital Virgen Macarena, Sevilla, Spain., Rodríguez-Pardo D; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0011), Instituto de Salud Carlos III, Madrid, Spain.; Servei de Malaties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain., De La Torre Cisneros J; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0011), Instituto de Salud Carlos III, Madrid, Spain.; Internal Medicine Department, University Hospital Reina Sofía, Córdoba, Spain., López Medrano F; Internal Medicine Department, University Hospital 12 de Octubre, Madrid, Spain., Cobo Reinoso J; Infectious Disease Department, University Hospital Ramon y Cajal, Madrid, Spain.; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0011), Instituto de Salud Carlos III, Madrid, Spain.; Instituto Ramón y Cajal Investigación Sanitaria (IRYCIS), Madrid, Spain.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2022 Jun 29; Vol. 77 (7), pp. 1996-2002.